logo-loader

BetterLife to present BETR-001 preclinical data at the American College of Neuropsychopharmacology meeting in Phoenix

Published: 09:24 02 Dec 2022 EST

BetterLife Pharma Inc - BetterLife to present BETR-001 preclinical data at the American College of Neuropsychopharmacology meeting in Phoenix
“We hope to file its investigational new drug application and begin human trials by mid-2023,” said BetterLife CEO Dr Ahmad Doroudian

BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) said that one of its scientific collaborators, Dr Argel Aguilar-Valles from Carleton University’s Department of Neuroscience, will make a presentation on the anti-depressant activity of the company’s lead compound, its proprietary 2-bromo-LSD (BETR-001), at the four-day American College of Neuropsychopharmacology (ACNP) annual conference in Phoenix, Arizona starting on December 4, 2022. 

The Vancouver, British Columbia-based biotech’s BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide (LSD) derivative molecule. 

According to BetterLife, Dr Aguilar-Valles will present preclinical data supporting the acute and long-term anti-depressant activity of BETR-001 monotherapy in animal models. “The data shows that BETR-001 promotes structural neuroplasticity in brain neurons and this effect is partly mediated by the activation of 5-HT2A receptor,” said the company. 

READ: BetterLife Pharma files comprehensive patent for BETR-001 and other LSD derivatives

In a statement, BetterLife CEO Dr Ahmad Doroudian said: “BETR-001 is a uniquely positioned LSD derivative with the potential to be as effective as LSD in various neuropsychiatric and neurological disorders without the burden of being hallucinogenic.”

“Because of its non-hallucinogenic nature, BETR-001 will not have all the LSD requirements of administration in specialized clinics under special treatment protocols. The LSD-controlled substance has regulatory issues which impact manufacturing, distribution, and patient access, and the overall associated high treatment costs for all these parameters.”

BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent for composition and method of use covers the treatment of depression, cluster headaches, post-traumatic stress disorder, and other neuropsychiatric and neurological disorders.

“BETR-001 is protected by BetterLife’s composition, method-of-use, synthesis, and formulation patents both issued and provisional,” said Dr Doroudian.

Betterlife said that BETR-001’s preclinical and IND-enabling studies are being completed.

“We hope to file its investigational new drug application (IND) and begin human trials by mid-2023,” said Dr Doroudian.

BetterLife Pharma is primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuropsychiatric and neurological disorders. BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol and the company’s pending method of use and formulations patent covers the treatment of anxiety-related disorders, including benzodiazepine dependency.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Ramp Metals Launches Drilling Program in Pursuit of High-Grade Nickel in...

Ramp Metals CEO Jordan Black joined Steve Darling from Proactive to introduce the company to the public domain and share exciting developments in the mining industry. With a background as a geotechnical engineer and experience in venture capital, including a notable role in taking GoldSpot...

51 minutes ago